Rineterkib
- Generic Name
- Rineterkib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27BrF3N5O2
- CAS Number
- 1715025-32-3
- Unique Ingredient Identifier
- 15KFN616FK
- Background
Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
- Associated Conditions
- -
- Associated Therapies
- -
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath